Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 13, 2012

View Archived Issues

TOCA therapy increases survival in models of brain cancer

Sanofi prepares novel fibroblast growth factor receptor antagonists

Zalicus and Hydra Biosciences to collaborate on ion channel modulators

Washington University study reveals mechanisms behind AML relapse

Phase IIb data on iferanserin support ongoing phase III study

Algeta reports updated data from phase III ALSYMPCA trial

FDA warns of drug interactions with Victrelis

FDA warns for increased risk of CDI-associated diarrhea with proton pump inhibitor use

Pergamum completes recruitment in PXL-01 study

Zealand Pharma to receive milestone payment following completion of GetGoal program

FDA issues draft guidance to assist industry in developing biosimilar products

Dainippon Sumitomo Pharma updates progress of third quarter of fiscal 2011

Santarus commences study of Uceris added to 5-ASA therapy

Advinus Therapeutics and Celgene Global Health enter collaboration

Large phase II trial assesses meningococcal vaccine in infants

Pfizer launches Inlyta in U.S.

Insmed to proceed with clinical studies of Arikace in U.S. and Europe

Kaken Pharmaceutical patents new ADAM inhibitors

U.S. university designs new siRNA products for Sjogren's syndrome

Dicerna Pharmaceuticals patents new RNA-based products

New anticancer products developed

Zhe-Jiang Beta Pharma presents novel PARP-1 inhibitors

Bayer reports novel candidate cancer therapeutics

Novartis receives response from FDA regarding Menveo sBLA

UCB Pharma enters collaboration with Nodality

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 8, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 8, 2025.
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...